Lee Ainslie’s Moderna MRNA Stock Holding History

Lee Ainslie’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-2,277	Closed	-$238K	–	814
2020 Q4	$238K	Buy	+2,277	New	+$230K	﹤0.01%	501

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BPC

Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return

Lee Ainslie's MRNA Position: Q1 2021 in Review

Lee Ainslie sold out of Moderna (MRNA) in Q1 2021, closing a stake of 2,277 shares — an estimated $238K sold.

Lee Ainslie first reported a position in MRNA in Q4 2020 and held it in 1 quarter. The position peaked at $238K in Q4 2020. 777 funds tracked by Wall St. Rank hold MRNA as of Q1 2021.

Lee Ainslie reported no remaining Moderna position as of Q1 2021 after selling out during the quarter.
Lee Ainslie sold 2,277 Moderna shares in Q1 2021, an estimated $238K.
Lee Ainslie first reported a position in Moderna in Q4 2020 and held it in 1 quarter.
Lee Ainslie's Moderna position peaked at $238K in Q4 2020.
777 funds tracked by Wall St. Rank held Moderna as of Q1 2021.

Based on Maverick Capital's 13F filing for Q1 2021, filed 17 May 2021.